Jun 10, 2014
Actavis Finalizes Agreement Related to Asacol HD Patent Challenge Litigation
Actavis has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol HD delayed-release tablets.
Research and Markets: Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, EU, Japan, and Canada.
Shire buying liver disease drug maker for $260M
Irish drugmaker Shire said Monday it will buy privately-held Lumena Pharmaceuticals for more than $260 million in a deal that gives Shire new experimental treatments for liver diseases.
Press release distribution, EDGAR filing, XBRL, regulatory filings
Dr. Von Hoff is curren... )--ORBCOMM Inc. , a global provider of Machine-to-Machine solutions, today announced that its senior management team will host a conference ca... )--TECO Energy Inc. today announced that the company will webcast its live presentation to the financial community at the American Gas Association Financial For... )--Global real ... (more)
Dr. Roach: No evidence narcotics can help heal colitis
Dear Dr. Roach : I have a very close relative who has ulcerative colitis and who was very ill a few years ago.